Want to see MLEC full AI Analyst Report?
MLEC Stock Chart & Stats
$8.93
-$0.04(-4.25%)
At close: 4:00 PM EST
$8.93
-$0.04(-4.25%)
Day’s Range― - ―
52-Week Range$3.08 - $63.45
Previous CloseN/A
Volume11.69K
Average Volume (3M)209.37K
Market Cap
$5.08M
Enterprise Value$251.75M
Total Cash (Recent Filing)$1.93M
Total Debt (Recent Filing)$22.09M
Price to Earnings (P/E)―
Beta-0.15
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding726,118
10 Day Avg. Volume506,476
30 Day Avg. Volume209,369
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.12
P/FCF Ratio-1.35
Enterprise Value/Market Cap49.53
Enterprise Value/Revenue32.14
Enterprise Value/Gross Profit-393.66
Enterprise Value/Ebitda-48.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin ImprovementA dramatic FY2025 revenue ramp and gross margin expansion to ~34% indicate meaningful commercialization traction for Moolec’s plant-produced ingredients. Sustained higher margins point to improving unit economics and potential scalable revenue streams as processing and customer adoption grow over the next months.
Distinct Molecular Farming ModelMoolec’s core technology—engineering crops to yield animal-like proteins and oils—creates a differentiated product platform. This structural technological moat supports licensing, ingredient sales, and partnership models, offering barriers to entry for peers and long-term optionality across food-ingredient supply chains.
Regained Nasdaq Compliance And Equity IncreaseRecovering Nasdaq compliance and an improved equity base via conversions and related-party funding materially reduce immediate delisting risk and preserve access to U.S. capital markets. This structural repair to the balance sheet enhances near-term financing optionality and supports operational continuity while commercialization scales.
Bears Say
Negative Equity And High LeverageMaterial negative equity and roughly $246.9M of debt create a fragile capital structure that limits strategic flexibility. High leverage elevates refinancing and solvency risk, can constrain partnership or licensing negotiations, and increases the likelihood of equity dilution or costly financing over the coming months.
Sustained Cash Burn And Negative FCFPersistent operating cash outflows and negative free cash flow signal ongoing reliance on external funding to support operations and scale commercialization. Continued cash burn pressures liquidity, raises refinancing needs, and risks interrupting product rollouts or partnerships if capital access tightens over the medium term.
Legal And Governance DisputesA winding‑up petition and disputed legacy legal claims create direct solvency and governance uncertainty, block issuance of Returning Holdback Amounts, and can restrict corporate actions. Such disputes are structurally distracting, may incur cash payouts or settlements, and could harm counterparty trust and execution over months.
Moolec Science News
MLEC FAQ
What was Moolec Science’s price range in the past 12 months?
Moolec Science lowest stock price was $3.08 and its highest was $63.45 in the past 12 months.
What is Moolec Science’s market cap?
Moolec Science’s market cap is $5.08M.
When is Moolec Science’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Moolec Science’s earnings last quarter?
Currently, no data Available
Is Moolec Science overvalued?
According to Wall Street analysts Moolec Science’s price is currently Overvalued.
Does Moolec Science pay dividends?
Moolec Science does not currently pay dividends.
What is Moolec Science’s EPS estimate?
Moolec Science’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moolec Science have?
Moolec Science has 726,118 shares outstanding.
What happened to Moolec Science’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Moolec Science?
Currently, no hedge funds are holding shares in MLEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moolec Science
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas. The company is based in Grand Cayman, Cayman Islands.
Technical Analysis
AIM ImmunoTech
―
Ensysce Biosciences
―
Cyclerion Therapeutics
―
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
― Other Institutional Investors
99.99% Public Companies and
Individual Investors